The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial
This study aims to prove both the non-inferiority in leiomyoma volume reduction and superiority in adverse effects occurrence reduction, which will provide a novel method to escape adverse effects while maintaining the effect of leiomyoma reduction.Trial registrationJapan Registry of Clinical Trials jRCTs051230078. Registered on 26 July 2023.
Source: Trials - Category: Research Source Type: clinical trials
More News: Anemia | Bleeding | Clinical Trials | Estradiol | Hormones | Leiomyoma | Men | Menopause | Orthopaedics | Osteoporosis | Research | Study | Women